Development and validation of a questionnaire evaluating the impact of hepatitis B immune globulin prophylaxis on the quality of life of liver transplant recipients

Liver Transplantation

Volumn 18, Issue 3, 2012, Pages 332-339

  Franciosi, Monica ^a   Caccamo, Lucio ^b   De Simone, Paolo ^c   Pinna, Antonio Daniele ^d   Di Costanzo, Giovanni Giuseppe ^e   Volpes, Riccardo ^f   Scuderi, Vincenzo ^e   Strignano, Paolo ^g   Boccagni, Patrizia ^h   Burra, Patrizia ^h   Nicolucci, Antonio ^a  

^a Mario Negri Sud Consortium ^*  (Italy)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^c UNIVERSITY HOSPITAL OF PISA   (Italy)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e CARDARELLI HOSPITAL   (Italy)

^f MEDITERRANEAN INSTITUTE FOR TRANSPLANTATION AND ADVANCED SPECIALIZED THERAPIES ISMETT   (Italy)

^g MOLINETTE HOSPITAL   (Italy)

^h UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B ANTIBODY;

ADULT; ARTICLE; CLINICAL ARTICLE; DAILY LIFE ACTIVITY; DEMOGRAPHY; FEMALE; GRAFT RECIPIENT; HUMAN; IMMUNOGLOBULIN THERAPY AFTER LIVER TRANSPLANTATION QUESTIONNAIRE; LIVER TRANSPLANTATION; MALE; PATIENT SATISFACTION; PRIORITY JOURNAL; PSYCHOMETRY; QUALITY OF LIFE; QUALITY OF LIFE INDEX; STRUCTURED QUESTIONNAIRE;

ADOLESCENT; ADULT; AGE FACTORS; AGED; FEMALE; HEPATITIS B; HUMANS; IMMUNOGLOBULINS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; QUALITY OF LIFE; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS;

EID: 84857524640     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.22473     Document Type: Article

References (20)

1. Busuttil RW, Farmer DG, Yersiz H, Hiatt JR, McDiarmid SV, Goldstein LI, et al. Analysis of long-term outcomes of 3200 liver transplantations over two decades: a single-center experience. Ann Surg 2005; 241: 905-916.
2. National Institutes of Health consensus development conference statement: liver transplantation June 20-23, 1983. Hepatology 1984; 4 (suppl): 107S-110S.
3. Cholongitas E, Goulis J, Akriviadis E, Papatheodoridis GV,. Hepatitis B immunoglobulin and/or nucleos(t)ide analogues for prophylaxis against hepatitis B virus recurrence after liver transplantation: a systematic review. Liver Transpl 2011; 17: 1176-1190.
4. Han SH, Ofman J, Holt C, King K, Kunder G, Chen P, et al. An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy. Liver Transpl 2000; 6: 741-748.
5. Shouval D, Samuel D,. Hepatitis B immune globulin to prevent hepatitis B virus graft reinfection following liver transplantation: a concise review. Hepatology 2000; 32: 1189-1195.
6. Lok AS,. Prevention of recurrent hepatitis B post-liver transplantation. Liver Transpl 2002; 8 (suppl 1): S67-S73. (Pubitemid 35154046)
7. Angus PW, McCaughan GW, Gane EJ, Crawford DH, Harley H,. Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B. Liver Transpl 2000; 6: 429-433. (Pubitemid 30489114)
8. Spilker B,. Quality of Life and Pharmacoeconomics in Clinical Trials. 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 1995: 49-56.
9. Stone DH,. Design a questionnaire. BMJ 1993; 307: 1264-1266. (Pubitemid 23330513)
10. Cronbach LJ,. Coefficient alpha and the internal structure of tests. Psychometrika 1951; 16: 297-334.
11. Ware JE Jr, Harris WJ, Gandek B, Rogers BW, Reese PR,. MAP-R for Windows: Multitrait/Multi-Item Analysis Program Revised User's Guide. Boston, MA: Health Assessment Lab; 1997.
12. Howard KI, Forehand GG,. A method for correcting item-total correlation for the effect of relevant item inclusion. Educ Psychol Meas 1962; 22: 731-735.
13. Campbell DT, Fiske DW,. Convergent and discriminant validation by the multitrait-multimethod matrix. Psychol Bull 1959; 56: 81-105.
14. Kodraliu G, Mosconi P, Groth N, Carmosino G, Perilli A, Gianicolo EA, et al. Subjective health status assessment: evaluation of the Italian version of the SF-12 health survey. Results from the MiOS project. J Epidemiol Biostat 2001; 6: 305-316. (Pubitemid 33138821)
15. Samsa G, Edelman D, Rothman ML, Williams GR, Lipscomb J, Matchar D,. Determining clinically important differences in health status measures: a general approach with illustration to the Health Utilities Index Mark II. Pharmacoeconomics 1999; 15: 141-155. (Pubitemid 29093257)
16. Gandek B, Ware JE Jr, Aaronson NK, Alonso J, Apolone G, Bjorner J, et al. Tests of data quality, scaling assumptions, and reliability of the SF-36 in eleven countries: results from the IQOLA project. International Quality of Life Assessment. J Clin Epidemiol 1998; 51: 1149-1158. (Pubitemid 28527170)
17. Yahyazadeh A, Beckebaum S, Cicinnati V, Klein C, Paul A, Pascher A, Neuhaus R,. Efficacy and safety of subcutaneous human HBV-immunoglobulin (Zutectra) in liver transplantation: an open, prospective, single-arm phase III study. Transpl Int 2011; 24: 441-450.
18. Gove WR,. Gender differences in mental and physical illness: the effects of fixed roles and nurturant roles. Soc Sci Med 1984; 19: 77-91.
19. Gijsbers van Wijk CM, van Vliet KP, Kolk AM, Everaerd WT,. Symptom sensitivity and sex differences in physical morbidity: a review of health surveys in the United States and the Netherlands. Women Health 1991; 17: 91-124.
20. Jin S, Yan L, Li B, Wen T, Zhao J, Zeng Y, et al. Quality of life and psychologic distress of recipients after adult living-donor liver transplantation (LDLT) a study from mainland China. Transplant Proc 2010; 42: 2611-2616.